Avalanche Biotechnologies Inc  

(Public, NASDAQ:AAVL)   Watch this stock  
Find more results for Paul Wachter
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 22.00 - 62.48
Open     -
Vol / Avg. 0.00/302,030.00
Mkt cap 970.86M
P/E     -
Div/yield     -
EPS -1.73
Shares 25.53M
Beta     -
Inst. own 71%
May 13, 2015
Q1 2015 Avalanche Biotechnologies Inc Earnings Release
Mar 25, 2015
Avalanche Biotechnologies Inc at the Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day
Mar 25, 2015
Avalanche Biotechnologies Analyst and Investor Day - Webcast
Mar 10, 2015
Avalanche Biotechnologies Inc at the Barclays Global Healthcare Conference - Webcast
Mar 5, 2015
Q4 2014 Avalanche Biotechnologies Inc Earnings Release
Mar 4, 2015
Avalanche Biotechnologies Inc at the Cowen and Company 35th Annual Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -4684.24% -4441.26%
Operating margin -4709.85% -4301.75%
EBITD margin - -4237.76%
Return on average assets -16.78% -31.17%
Return on average equity -17.77% -40.54%
Employees 64 -
CDP Score - -


1035 O?Brien Drive, Suite A
United States - Map
+1-650-2726269 (Phone)
+1-650-3621908 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Avalanche Biotechnologies, Inc. (Avalanche) is clinical-stage biotechnology company. The Company is focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. The Company operates through a single segment, being the business of developing and commercializing therapeutics. Avalanche's Ocular BioFactory platform technology is a proprietary adeno-associated virus (AAV)-based gene therapy discovery and development technology optimized for ophthalmology that utilizes a directed evolution approach to generate novel drug candidates. The Company’s lead product candidate, AVA-101 is used for the treatment of wet age-related macular degeneration (AMD). The Company’s AVA-201 is a next generation anti-VEGF gene therapy product candidate, which is being developed for the prevention of wet AMD. In addition, Avalanche’s AVA-311 is being developed for the treatment of Juvenile X-linked Retinoschisis (XLRS).

Officers and directors

Mark S. Blumenkranz M.D. Chairman of the Board, Co-Founder
Age: 64
Bio & Compensation  - Reuters
Thomas W Chalberg Jr President, Chief Executive Officer, Director
Age: 37
Bio & Compensation  - Reuters
Steven D. Schwartz M.D. Co-Founder, Director
Age: 53
Bio & Compensation  - Reuters
Linda C. Bain CPA Chief Financial Officer, Treasurer
Age: 44
Bio & Compensation  - Reuters
Hans P. Hull Senior Vice President - Legal and Corporate Development
Age: 40
Bio & Compensation  - Reuters
Roman G. Rubio M.D. Senior Vice President and Head - Translational Medicine
Age: 44
Bio & Compensation  - Reuters
Mehdi Gasmi Ph.D. Vice President - Pharmaceutical Development
Age: 48
Bio & Compensation  - Reuters
Samuel B. Barone M.D. Chief Medical Officer
Age: 42
Bio & Compensation  - Reuters
John P. McLaughlin Director
Age: 63
Bio & Compensation  - Reuters
Paul D. Wachter Director
Age: 58
Bio & Compensation  - Reuters